| Issue Date | Title | Author(s) |
| 2019 | Analysis of pentaterpenoids | Blundell, Renald; Azzopardi, Joseph; Briffa, Jessica; Rasul, Azhar; Vargas-de la Cruz, Celia; Ajmal Shah, Muhammad |
| 2014 | Beware the person with the glass eye and the large liver | Vassallo, Edith; Azzopardi, Christine; Pullicino, Richard; Grech, Reuben |
| 2024 | A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms | Camilleri, Emma; Blundell, Renald; Baral, Bikash; Karpinski, Tomasz M.; Aruci, Edlira; Atrooz, Omar M. |
| 2009 | IGBP1 protein as a regulator of mTOR pathway and its role in haematopoiesis | Borg, Nigel; Grech, Godfrey |
| 2002 | Insulin-like growth factor (IGF)-independent effects of IGF binding protein-4 on human granulosa cell steroidogenesis | Wright, Rebecca J.; Holly, Jeffrey M. P.; Galea, Raymond P.; Brincat, Mark; Mason, Helen D. |
| 2021 | Investigating mechanisms involved in the pharmacology of non-small cell lung cancer | Cilia, Dustin (2021) |
| 2019-05 | Opinions of decision-makers on the clinical development and assessment of antineoplastic agents | Said, Dylan; Borg, John-Joseph; Attard Pizzuto, Maresca; Serracino-Inglott, Anthony |
| 2018 | Patients’ lived experiences of cytotoxic medications prescribed for the management of malignant solid tumours : a systematic review | Brincat, Alison; Stewart, Derek; Weidmann, Anita; Vella Bonanno, Patricia |
| 2020 | Patients’ lived experiences with antineoplastic medicines for the management of malignant solid tumours : a systematic review | Brincat, Alison; Vella Bonanno, Patricia; Stewart, Derek; Weidmanna, Anita E. |
| 2018 | Patients’ lived experiences with antineoplastic medicines prescribed for the management of malignant solid tumours : a systematic review | Brincat, Alison; Stewart, Derek; Vella Bonanno, Patricia; Weidmann, Anita E. |
| 2021 | Patients’ misconceptions following initiation of antineoplastic treatment for colorectal cancer | Brincat, Alison; Vella Bonanno, Patricia; Stewart, Derek; Weidmann, Anita E. |
| 2018 | pH-triggered release of gefitinib : a potent anticancer agent | Vella, Chelsey (2018) |
| 2018-11 | Pharmacogenetic testing for drugs used in malignancy | Xuereb, Althea Marie; Wirth, Francesca; Mifsud Buhagiar, Luana; Serracino-Inglott, Anthony |
| 2017-03 | Practical implications in shelf-life extension of anticancer admixtures | Said, Dylan; Galea, Sylvania; Sammut Bartolo, Nicolette; Serracino-Inglott, Anthony; Azzopardi, Lilian M. |
| 2020 | The rational design of acid ceramidase inhibitors | Abela, Gabriel |
| 2024 | Recent progress of protein kinase inhibitors derived from marine peptides for developing anticancer agents | Zheng, Lanhong; Wei, Ning; Farooqi, Ammad Ahmad; Zhang, Yan; Blundell, Renald; Liu, Xiujun; Xu, Yixin; Lin, Xiukun |
| 2018 | Systematic review contributing to an understanding of the patients' lived experience with medicines with reference to antineoplastic medicines | Brincat, Alison; Stewart, Derek; Vella Bonanno, Patricia; Weidmann, Anita E. |
| 2020 | Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case study with olaratumab | Pontes, Caridad; Zara, Corinne; Torrent-Farnell, Josep; Obach, Merce; Nadal, Christina; Vella Bonanno, Patricia; Ermisch, Michael; Simoens, Steven; Hauegen, Renata Curi; Gulbinovic, Jolanta; Timoney, Angela; Mueller, Tanja; Martin, Anthony P.; Nachtnebel, Anna; Campbell, Stephen; Selke, Gisbert; Bochenek, Tomasz; Rothe, Celia; Mardare, Ileana; Bennie, Marion; Fürst, Jurij; Malmstrom, Rickard E.; Godman, Brian |
